Overcoming Taxane and Anthracycline Resistance
Article first published online: 12 APR 2010
© 2010 Wiley Periodicals, Inc.
The Breast Journal
Volume 16, Issue 3, pages 309–312, May/June 2010
How to Cite
Zelnak, A. (2010), Overcoming Taxane and Anthracycline Resistance. The Breast Journal, 16: 309–312. doi: 10.1111/j.1524-4741.2010.00911.x
- Issue published online: 5 MAY 2010
- Article first published online: 12 APR 2010
- metastatic breast cancer;
Abstract: With more and more breast cancer (BC) patients receiving taxanes and anthracyclines in the adjuvant setting, the number of patients resistant to these drugs is rising. Herein, we review cellular mechanisms (e.g., overexpression of drug efflux pumps) that are associated with clinical anthracycline and/or taxane-resistant BC. We also discuss therapeutic approaches that have received Food and Drug Administration approval in this setting or are in clinical development, including targeted agents that do not employ a cytotoxic mechanism, as well as novel chemotherapeutics such as the epothilones, a class of microtubule stabilizers less susceptible to common cellular resistance mechanisms.